Krajina: Nový Zéland
Jazyk: angličtina
Zdroj: Medsafe (Medicines Safety Authority)
Estriol 0.5mg
Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics
Estriol 0.5 mg
0.5 mg
Pessary
Active: Estriol 0.5mg Excipient: Hard fat
Blister pack, PVC, 15 pessaries
Prescription
Prescription
NV Organon
Atrophy of the lower urogenital tract related to oestrogen deficiency, notably · for the treatment of vaginal complaints such as dyspareunia, dryness and itching. · for the prevention of recurrent infections of the vagina and lower urinary tract. · in the management of micturition complaints (such as frequency and dysuria) and mild urinary incontinence.
Package - Contents - Shelf Life: Blister pack, PVC - 15 pessaries - 3 years from date of manufacture stored at 2 - 25°C. Store in original package. Avoid excessive heat protect from light and moisture
2010-09-21
_NEW ZEALAND DATA SHEET _ 1 Ovestin Ovula A131014 Version 4.0 RA 170 CCDS 9 (Ref.: 6.0) OVESTIN ® OVULA Oestriol NAME OF MEDICINE Ovestin Ovula Pessary Oestriol 0.5 mg PRESENTATION Each pack of Ovestin Ovula contains 3 strips of 5 white, torpedo formed pessaries. One pessary (2.5 g weight) contains 0.5 mg oestriol. Length 26.5 mm; largest diameter 14 mm. USES ACTIONS Pharmacotherapeutic group: natural and semisynthetic oestrogens ATC code: G03C A04 Ovestin Ovula contains the natural female hormone oestriol. Unlike other oestrogens, oestriol is short acting since it has only a short retention time in the nuclei of endometrial cells. It substitutes for the loss of oestrogen production in menopausal women and alleviates menopausal symptoms. Oestriol is particularly effective in the treatment of urogenital symptoms. In case of atrophy of the lower urogenital tract oestriol induces the normalization of the urogenital epithelium and helps to restore the normal microflora and the physiological pH in the vagina. As a result, it increases the resistance of the urogenital epithelial cells to infection and inflammation reducing vaginal complaints such as dyspareunia, dryness, itching, vaginal and urinary infections, micturition complaints and mild urinary incontinence. Clinical trial information • Relief of menopausal symptoms was achieved during the first weeks of treatment. • Vaginal bleeding after treatment with Ovestin Ovula has only rarely been reported. PHARMACOKINETICS Absorption Intravaginal administration of oestriol ensures optimal availability at the site of action. Oestriol is also absorbed into the general circulation as is shown by a sharp rise in the plasma levels of unconjugated oestriol. Peak plasma levels are reached 1-2 hours after application. After va Prečítajte si celý dokument